Medizinische Universität Graz Austria/Österreich - Forschungsportal - Medical University of Graz
Gewählte Publikation:
SHR Neuro Krebs Kardio Lipid Stoffw Microb
Pilz, S; Gaksch, M; Kienreich, K; Grübler, M; Verheyen, N; Fahrleitner-Pammer, A; Treiber, G; Drechsler, C; Ó, Hartaigh, B; Obermayer-Pietsch, B; Schwetz, V; Aberer, F; Mader, J; Scharnagl, H; Meinitzer, A; Lerchbaum, E; Dekker, JM; Zittermann, A; März, W; Tomaschitz, A.
Effects of vitamin D on blood pressure and cardiovascular risk factors: a randomized controlled trial.
Hypertension. 2015; 65(6):1195-201
Doi: 10.1161/HYPERTENSIONAHA.115.05319
[OPEN ACCESS]
Web of Science
PubMed
FullText
FullText_MUG
- Führende Autor*innen der Med Uni Graz
- Keppel Martin Helmut
- Kienreich Katharina
- Pilz Stefan
- Co-Autor*innen der Med Uni Graz
- Aberer Felix
- Fahrleitner-Pammer Astrid
- Grübler Martin
- Lerchbaum Elisabeth
- Mader Julia
- März Winfried
- Meinitzer Andreas
- Obermayer-Pietsch Barbara
- Scharnagl Hubert
- Theiler-Schwetz Verena
- Tomaschitz Andreas
- Treiber Gerlies
- Verheyen Nicolas Dominik
- Altmetrics:
- Dimensions Citations:
- Plum Analytics:
- Scite (citation analytics):
- Abstract:
- UNLABELLED: Vitamin D deficiency is a risk factor for arterial hypertension, but randomized controlled trials showed mixed effects of vitamin D supplementation on blood pressure (BP). We aimed to evaluate whether vitamin D supplementation affects 24-hour systolic ambulatory BP monitoring values and cardiovascular risk factors. The Styrian Vitamin D Hypertension Trial is a single-center, double-blind, placebo-controlled study conducted from June 2011 to August 2014 at the endocrine outpatient clinic of the Medical University of Graz, Austria. We enrolled 200 study participants with arterial hypertension and 25-hydroxyvitamin D levels below 30 ng/mL. Study participants were randomized to receive either 2800 IU of vitamin D3 per day as oily drops (n=100) or placebo (n=100) for 8 weeks. Primary outcome measure was 24-hour systolic BP. Secondary outcome measures were 24-hour diastolic BP, N-terminal-pro-B-type natriuretic peptide, QTc interval, renin, aldosterone, 24-hour urinary albumin excretion, homeostasis model assessment-insulin resistance, triglycerides, high-density lipoprotein cholesterol, and pulse wave velocity. A total of 188 participants (mean [SD] age, 60.1 [11.3] years; 47% women; 25-hydroxyvitamin D, 21.2 [5.6] ng/mL) completed the trial. The mean treatment effect (95% confidence interval) for 24-hour systolic BP was -0.4 (-2.8 to 1.9) mm Hg (P=0.712). Triglycerides increased significantly (mean change [95% confidence interval], 17 [1-33] mg/dL; P=0.013), but no further significant effects were observed for secondary outcomes. Vitamin D supplementation in hypertensive patients with low 25-hydroxyvitamin D has no significant effect on BP and several cardiovascular risk factors, but it was associated with a significant increase in triglycerides. CLINICAL TRIAL REGISTRATION: URL: http://www.clinicaltrials.gov. Unique identifier: NCT02136771.
- Find related publications in this database (using NLM MeSH Indexing)
- Aged - administration & dosage
- Austria - administration & dosage
- Blood Pressure - drug effects, physiology
- Blood Pressure Determination - administration & dosage
- Cardiovascular Diseases - prevention & control
- Dietary Supplements - administration & dosage
- Double-Blind Method - administration & dosage
- Female - administration & dosage
- Follow-Up Studies - administration & dosage
- Hospitals, University - administration & dosage
- Humans - administration & dosage
- Hypertension - diagnosis, drug therapy
- Male - administration & dosage
- Middle Aged - administration & dosage
- Prospective Studies - administration & dosage
- Reference Values - administration & dosage
- Risk Assessment - administration & dosage
- Severity of Illness Index - administration & dosage
- Treatment Outcome - administration & dosage
- Vitamin D - administration & dosage
- Find related publications in this database (Keywords)
- blood pressure
- cholecalciferol
- placebo
- randomized controlled trial
- vitamin D